The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients by unknown
The psychometric properties of the Migraine-Specific Quality
of Life Questionnaire version 2.1 (MSQ) in chronic migraine
patients
Regina Rendas-Baum • Lisa M. Bloudek •
Gregory A. Maglinte • Sepideh F. Varon
Accepted: 25 June 2012 / Published online: 15 July 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Objective The Migraine-Specific Quality of Life Ques-
tionnaire version 2.1 (MSQ) has been shown to have good
psychometric performance in measuring headache impact
in migraine patients, but its properties specifically in
chronic migraine (CM) patients are unknown. The objec-
tive of this study was to evaluate the psychometric prop-
erties of the MSQ in a group of CM patients undergoing
prophylactic treatment.
Methods Measurement properties of the MSQ were
examined using two international, multicenter, randomized
clinical trials evaluating onabotulinumtoxinA as headache
prophylaxis in CM patients (N = 1,376). Confirmatory
factor analysis (CFA) was used to test the latent structure
of the MSQ in CM patients. The reliability, convergent and
discriminant validity, and responsiveness of the MSQ were
assessed.
Results CFA confirmed the currently proposed three-factor
MSQ latent structure across the two studies. Good reliability
was observed for all three MSQ scales, across studies and time
points. MSQ scale scores strongly correlated with the scores of
the Headache Impact Test-6 (HIT-6). Analysis of known-
groups validity indicated that MSQ scale scores discriminated
between groups of patients differing in their 28-day headache
frequency were as follows\10, 10–14, and C15 days, and the
sample-derived quartiles of the total cumulative hours of
headache were as follows\140, 140 to\280, 280 to\420,
and C420 h (p \ 0.0001), across both studies and time points.
MSQ change scores were higher in magnitude in groups
experiencing greater decline in headache frequency
(p \ 0.001).
Conclusion The MSQ is a psychometrically valid tool
that can be used to reliably measure the impact of migraine
among CM patients.
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Introduction
Migraine attacks are characterized by severe pain and may
be accompanied by nausea, photosensitivity, or other
migraine-associated symptoms leading to substantial dis-
ability [1]. As a result, migraine disorder has been shown to
significantly impact health-related quality of life (HRQL)
both during and between attacks [2, 3]. It is expected that
treatment that effectively reduces migraine-associated
symptoms or the frequency of headaches will also improve
patient’s HRQL. Indeed, experts have recommended [4, 5]
the use of disease-specific patient-reported outcome (PRO)
measures to quantify the potential benefits of treatment in
migraine clinical trials.
The Migraine-Specific Quality of Life Questionnaire ver-
sion 2.1 (MSQ) is a 14-item PRO instrument that measures the
impact of migraine across three essential aspects of a patient’s
HRQL over the past 4 weeks: role function-restrictive (RR),
role function-preventive (RP), and emotional function (EF).
The MSQ’s conceptual framework was developed from an
expert review of the migraine literature and subsequently
validated in a clinical sample of 458 migraine patients [6].
Furthermore, several studies [7–10] have further demon-
strated that the MSQ possesses good psychometric properties
among migraine patients.
Studies have suggested that migraine patients who
experience a greater frequency of headache attacks are
subjected to significantly greater levels of disability and
reduced health-related quality of life [11, 12]. Differences
in the frequency of migraine attacks have also been linked
to clinical and pathophysiologic features of migraine.
Migraine can be divided into episodic migraine (EM) and
chronic migraine (CM), based on the frequency of head-
ache days. CM is characterized by the International Clas-
sification of Headache Disorders revised criteria (ICHD-II)
as experiencing 15 or more headache days per month for at
least 3 months with at least 8 days per month being
migraine days. CM is a subtype of chronic daily headache,
and evidence suggests that CM patients experience neu-
rological alterations even in the absence of headache,
which differs from the intermittent changes noted in EM
(\15 headache days/month) during headache attacks [13,
14]. Furthermore, it has been observed that CM patients
exhibit lower pain thresholds when compared to patients
with EM [15].
Although the MSQ has been shown to have good psy-
chometric performance in measuring headache impact
across CM and EM patients [16], the assumption that its
validity is retained across these clinical subgroups has not
been verified. Given the extensive use of the MSQ in
migraine research and practice [6, 7, 17–19] and the
emerging evidence regarding several distinguishing char-
acteristics of CM when compared to EM patients, studies
assessing the validity of the MSQ specifically in CM are
needed. The current study aims to provide evidence of the
psychometric properties of the MSQ using data from two




Data used in these analyses came from a total sample of
1,376 CM patients who participated in 2 studies that
evaluated onabotulinumtoxinA (BOTOX, Allergan, Inc.,
Irvine, CA) as headache prophylaxis—the Phase III
REsearch Evaluating Migraine Prophylaxis Therapy
(PREEMPT) trials with Botulinum Toxin Type A [20, 21].
Both PREEMPT trials were multicenter, double-blind,
randomized, placebo-controlled, with a 24-week parallel-
group phase followed by an open-label 32-week extension.
All analyses were conducted by pooling treatment groups.
To be considered eligible for the trial, participants had to
be between the ages of 18 and 65 and fulfill each of the
following headache-related criteria: (1) history of migraine
headache disorder meeting any of the diagnostic criteria
listed in ICHD-II [22] section 1, for migraine, with the
exception of ‘‘complicated migraine’’; (2) C4 distinct
headache episodes each with a duration of at least 4 h
during the 4-week baseline phase; (3) C15 headache days
during the 4-week baseline phase, with each headache day
consisting of C4 h of continuous headache; and (4) C50 %
of baseline headache days were migraine or probable
migraine days. Headache-related exclusion criteria inclu-
ded any of the following criteria: (1) diagnosis of com-
plicated migraine, basilar migraine, ophthalmoplegic
migraine, or migrainous infarction; (2) use of any headache
prophylactic medication within 28 days prior to screening;
(3) diagnosis of chronic tension-type headache, hypnic
headache, hemicrania continua, or new daily persistent
headache; (4) headache attributed to another disorder (e.g.,
cervical dystonia, craniotomy, head/neck trauma); and (5)
unremitting headache lasting continuously throughout the
4-week baseline period. In addition, participants with a
Beck Depression Inventory score [ 24 at week 4 baseline
period were also excluded.
Following the 4-week baseline phase, patients meeting
the inclusion/exclusion criteria were assigned in a blinded
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fashion to the study treatment in the strata of medication
overuse (yes/no), as determined by the frequency of acute
headache pain medication use during the baseline phase.
Within each stratum, patients were randomly allocated to
receive either onabotulinumtoxinA or placebo. In the
double-blind phase, participants received injections with
onabotulinumtoxinA at week 0 (baseline) and week 12.
Only data from the 24-week double-blinded period of the
two trials were used for the current study. As previously
reported, the PREEMPT studies were conducted in accor-
dance with the Declaration of Helsinki ethical principles,
Good Clinical Practices, principles of informed consent,
and requirements of public registration of clinical trials in
the United States. The studies were approved at each site
by an independent ethics committee or a local institutional
review board. Written informed consent was obtained from
each randomized participant prior to any study-related
procedures [20, 21].
Study measures
Migraine-Specific Quality of Life Questionnaire, version
2.1 (MSQ)
The 14-item MSQ is designed to measure how migraines
affect and/or limit daily functioning across three domains:
RR (7 items assessing how migraines limit one’s daily
social and work-related activities); PR (4 items assessing
how migraines prevent these activities); EF (3 items
assessing the emotions associated with migraines). Partic-
ipants respond to items using a 6-point scale: ‘‘none of the
time,’’ ‘‘a little bit of the time,’’ ‘‘some of the time,’’ ‘‘a
good bit of the time,’’ ‘‘most of the time,’’ and ‘‘all of the
time,’’ which are assigned scores of 1 to 6, respectively.
Raw dimension scores are computed as a sum of item
responses and rescaled from a 0 to 100 scale such that
higher scores indicate better quality of life.
Multiple studies have demonstrated good reliability and
validity of the MSQ in subjects with migraine [6–9]. The MSQ
has been administered in several efficacy trials of migraine
treatment and has been has shown to be responsive to treat-
ment effects [17, 18, 23]. Results from a study of 119 mi-
graineurs recruited at 4 headache clinics revealed that the
effect sizes of the MSQ were moderate to large at 4 and
12 weeks [24]. More recently, for each group, the minimally
important differences (MIDs) were estimated for the three
MSQ scales by an anchor-based approach using data from
both a clinical trial and a population-based study [10].
The Headache Impact Test-6 (HIT-6)
The HIT-6 was adapted from the longer, Internet-based
HIT [25], as a short pencil-and-paper survey assessing the
impact of headache on participants’ lives in the past
4 weeks. It is a brief instrument covering a broad content
of headache-related HRQL across the following domains:
pain, social functioning, role functioning, vitality, cogni-
tive functioning, and psychological distress. Each item is
answered on a 5-point Likert-scale (6 = never; 8 = rarely,
10 = sometimes, 11 = very often; 13 = always). The
currently recommended scoring of the HIT-6 was derived
to approximate the total score obtained from the larger
battery of items, using results from item response theory
[26]. The final score is obtained from simple summation of
the six items. The HIT-6 total score ranges between 36 and
78, with larger scores reflecting greater impact. Four
groups have been derived to aid in the interpretation of
HIT-6 scores: scores B 49 represent little or no impact,
scores between 50 and 55 represent some impact, scores
between 56 and 59 represent substantial impact, and
scores C 60 indicate severe impact [27].
Migraine diary
Using a self-administered diary, participants were asked to
report information on the start and stop time of any head-
ache, headache-specific characteristics and symptoms, and
use of any acute headache pain medication. A three-day
‘‘missing-recall’’ window was used, which allowed par-
ticipants to report this information for the current date and
for the 3 days immediately preceding it. If the 28-day diary
had at least 20 but less than 28 days of reported data, a
prorated approach was used. If a patient reported less than
20 days of headache data, the patient’s observed diary data
in that particular 28-day dairy was set to missing.
A headache day was defined as a day with 4 or more
continuous hours of headache. A migraine day was defined
as a day with 4 or more continuous hours of migraine
headache (ICHD-II criteria for migraine without aura or
migraine with aura). A probable migraine day is defined as
a day with 4 or more continuous hours of probable
migraine headache (ICHD-II for probable migraine).
Information on acute headache pain medication use was
used to define medication overuse.
Statistical analyses
The psychometric evaluation of the MSQ was conducted in
a sequential process. Data were first evaluated to determine
the comparability of the two study samples and the ade-
quacy of analytical approaches that may be sensitive to
distributional characteristics. Next, several analyses were
conducted to ensure the stability of the MSQ measurement
model. Confirmatory factor analysis (CFA) was employed
in order to ensure consistency with the currently proposed
MSQ measurement model. Upon the verification of the
Qual Life Res (2013) 22:1123–1133 1125
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stability of the MSQ measurement model, item-level psy-
chometric indicators were examined, followed by an
evaluation of the instrument’s reliability, construct validity,
and ability to detect change.
Measurement model
The latent structure of the MSQ was examined under CFA
using data collected at baseline. In addition to the currently
proposed three-factor model, other alternative domain
structures were fitted to test whether these would provide a
better fit to the data. CFA solutions were extracted using
the robust maximum likelihood (MLR) estimator in the
Mplus software, version 5.1 [28]. The MLR estimator
computes standard errors that are robust to non-normality.
The CFA model fit was assessed using several indicators:
comparative fit index (CFI), Tucker–Lewis Index (TLI),
and root mean square error of approximation (RMSEA).
Hu and Bentler’s guidelines [29] were used to interpret the
values of CFI and TLI (C.95), and RMSEA (\.06), indi-
cating a good fit. Standardized factor loadings and factor
correlations were also computed. High factor loadings
(C0.70) indicate convergent validity and support the
hypothesized relationships between items and the corre-
sponding latent factors (i.e., domains). Relatively lower
correlations between factors indicate discriminant validity
and support the domain structure of the MSQ.
Reliability
Indices of reliability reflect the consistency and reproduc-
ibility of scores produced by a particular measurement
procedure. Internal consistency reliability was evaluated by
examining the equivalence of responses within the MSQ in
a single administration. Internal consistency reliability of
the MSQ at baseline and week 24 was measured with three
indices: (1) Cronbach’s alpha, (2) the average inter-item
correlation [30], and (3) the item-total correlation after
correcting for overlap (i.e., after removing the item from
the total score). Cronbach’s alpha was evaluated against
currently recommended criteria [31]. Item-total correla-
tions and average inter-item correlations of 0.4 or higher
were deemed indicative of good reliability [32, 33].
Construct validity
Convergent validity
The convergent validity of the MSQ scores was assessed in
relation to HIT-6 scores. The Pearson correlation coefficient
was used to evaluate the degree of association between HIT-6
and those with MSQ scale scores. Correlation coefficients
were evaluated at baseline and at week 24.
Known-groups validity
Construct validity was also examined using the framework
of known-groups validity [34] by comparing mean MSQ
scale scores across groups known to differ on a clinical
criterion measure. Comparison groups were based on the
following clinical indicators of CM: (1) number of head-
ache days within a 28-day period and (2) cumulative hours
of headache within a 28-day period. Drawing on classifi-
cation criteria previously used in migraine research [35],
participants were classified into one of three headache
frequency categories based on frequency of headache days
per 28 days at the primary time point Week 24: \10,
10–14, or C15 headache days per 28 days. In addition, four
groups were formed based on quartiles of the sample’s
(combined study 1 and study 2) distribution of cumulative
hours of headache: (1) \140, (2) 140 to \280, (3) 280 to
\420, and (4) C420 h. These cutoffs corresponded to an
average of 5, 10, and 15 h of headache per day,
respectively.
Responsiveness
Responsiveness is a fundamental aspect of construct
validity that measures the instrument’s ability to detect
changes in health status. The responsiveness of the MSQ
was evaluated against changes (from baseline to week 24)
in frequency of headache days. Participants were catego-
rized according to the direction and magnitude of change in
these measures. If the 28-day frequency of headache days
improved (from day 0 to week 24) by at least 50 %, the
subject was categorized as ‘‘much improved’’; if
improvement was at least 30 % but less than 50 %, the
patient was considered to have ‘‘moderately improved’’; if
improvement was less than 30 % or if worsening was
reported, the patient was classified as ‘‘minimally/not
improved’’. We note that very few study participants
reported worsening of either frequency of headache days or
cumulative hours of headache. Hence, we opted to include
these patients in the same group as those reporting minimal
improvement (\30 %). Our criterion of change (30 % or
higher) is based on recommendations of the Task Force of
the International Headache Society Clinical Trials Sub-
committee [5]. F-tests obtained from the analysis of vari-
ance (ANOVA) models were used to evaluate whether the
differences in mean MSQ scale change score between
groups were statistically significant. The standardized
response mean (SRM), evaluated as the ratio of the mean
MSQ change score to its standard deviation, was evaluated
to help interpret the magnitude of change across the three
improvement groups defined above. A second set of anal-
ogous analyses was conducted after a term for medication
overuse was included in the model.




Table 1 presents the sample demographic and clinical char-
acteristics, by study. Overall, study participants were pri-
marily female, Caucasian, and had an average age of
approximately 41 years. On average, participants had been
experiencing frequent migraines for approximately 19 years
prior to study enrollment. Based on patients’ baseline
assessment, the average number of migraine days in a 28-day
period was approximately 16 (19 when probable migraine
days were also included). Approximately, 60 % of study
participants met the criteria for medication overuse.
Baseline scores on the MSQ and the HIT-6 were nearly
identical across the two studies. At baseline, the average
HIT-6 score was approximately 65 (65.6 and 65.3 for
studies 1 and 2, respectively), reflecting a severe level of
headache impact [27]. Scores on the MSQ were also
reflective of substantial impact on HRQL. The ranking of
MSQ domains in terms of impact was consistent across the
two studies, with migraine-attributable interruptions in
daily activities (RP domain) reflecting the lowest impact
and limitations due to migraine (RR domain) being the
most severely affected of the three MSQ domain.
Structural validity
Standard factor loadings indicated support for the three-factor
model of the MSQ, with factor loadings above 0.70 for all
items, except for item 12 (‘‘have you felt fed up or frustrated
because of your migraines?’’) (Table 2). The factor loadings
for item 12 ranged between 0.62 (study 1) and 0.67 (study 2).
The goodness of fit indices also suggested that the three-factor
model was an adequate representation of the latent structure
represented by the 14 items of the MSQ (study 1/study 2:
RMSEA [90 % confidence interval] = 0.06 [0.05–0.07]/0.06
[0.05–0.06]); CFI = 0.96/0.97; TLI = 0.96/0.96).
Given the slightly lower factor loadings and the
behavior of item-scale correlations observed for item 12
(see Table 3), two additional factor structures were fitted,
using data from each study in turn. The first model differed
from the three-factor MSQ model because item 12 was
allowed to load on the RR factor, rather than the EF factor
(it was noted that the correlations of item 12 with the EF
scale were nearly identical to the correlations with the RR
scale; see Table 3). Compared with the original three-fac-
tor model, this model resulted in similar goodness of fit
indicators (study 1/study 2: RMSEA [90 % confidence
interval] = 0.07/0.06 [0.06–0.08/0.06–0.07]), but the
loading of item 12 on the RR factor was substantially lower
(study 1/study 2: 0.56/0.58) than the factor loading of item
12 on the EF factor (study 1/study 2: 0.62/0.67), lending
support for the inclusion of item 12 in the EF factor.
It was also noted that the correlations between the three
factors were high (between 0.71 and 0.91 in study 1, and
between 0.72 and 0.87 in study 2; see Table 2), indicating
that a single factor model might be a good representation
for the MSQ latent structure. A single factor model was
thus fit to the data of each study separately to examine this
possibility. The single factor model resulted in poorer
goodness of fit indicators study 1/study 2: RMSEA [90 %
confidence interval] = 0.10 [0.09–0.11]/0.11 [0.10–0.11]);
CFI = 0.91/0.88; TLI = 0.89/0.86) and lower factor
loadings for the 3 items of the EF factor, when compared to
the three-factor structure.
Reliability
At baseline, Cronbach’s alpha was consistently at or above
the recommended threshold for good to excellent reliability





Age (years), mean (SD) 41.6 (10.5) 41.0 (10.6)
Gender, n (% female) 588 (87.5) 601 (85.4)
Race, n (%)
Caucasian 607 (90.3) 632 (89.8)
Black 30 (4.5) 44 (6.3)
Hispanic 29 (4.3) 17 (2.4)
Asian 3 (0.4) 4 (0.6)
Other 3 (0.4) 7 (1.0)
Migraine characteristics
Years since frequent migraine
onset, mean (SD)
20.5 (13.0) 18.0 (12.1)
Number of migraine days in a
28-day period, mean (SD)
16.5 (5.8) 16.3 (5.8)
Number of migraine/probable
migraine days in a 28-day period,
mean (SD)
19.1 (4.4) 18.9 (4.0)
Cumulative hours of headache in a
28-day period, mean (SD)
285.3 (114.3) 291.6 (119.6)
Analgesic medication overuse,
n (%)
457 (68.0) 443 (62.9)
MSQ
Total 56.6 (17.7) 54.6 (18.0)
Role function—preventive 44.6 (21.0) 43.3 (21.9)
Role function—restrictive 62.2 (16.8) 60.6 (16.9)
Emotional function 59.7 (24.1) 55.8 (24.8)
HIT-6, mean (SD) 65.6 (4.0) 65.3 (4.4)
HIT-6 varies between 36 and 78 with higher scores indicating higher
headache impact. The MSQ total and scale score varies between 0 and
100 with higher scores indicating higher impact
HIT-6 Headache Impact Test 6, MSQ Migraine-Specific Question-
naire, SD standard deviation
Qual Life Res (2013) 22:1123–1133 1127
123
(0.80) for all 3 scales, varying between 0.80 (EF) and 0.93
(RR) for study 1, and between 0.83 (EF) and 0.93 (RR) for
study 2 (Table 3). Internal consistency reliability was
equally high at week 24, with Cronbach’s alpha varying
between 0.90 and 0.97, across the three scales and the two
studies (results not shown). The relative contribution of each
item to the scale’s internal consistency was assessed by
evaluating alpha-removed statistics. The magnitude of
change in Cronbach’s alpha supported the notion of nearly
uniform contributions of each item to its scale. The only
exception occurred with the EF scale for which removal of
item 12 resulted in a small increase in the value of
Cronbach’s alpha (study 1/study 2 Cronbach’s alpha
change = 0.03/0.02). Item-total correlations were higher
than 0.40 across the two studies at both baseline and week 24,
supporting the validity of each item to the total scale. Slightly
lower values were observed for item 12 for which baseline
item-total correlations were 0.54 and 0.59 for study 1 and 2,
respectively. Correlations between item 12 and the total EF
score after removing item 12 from the scale were higher at
week 24 (study 1/study 2: 0.78/0.73, not shown). At baseline,
the average inter-item correlation was (study 1/study 2) 0.71/
0.70, 0.70/0.71, and 0.61/0.66 for the RR, RP, and EF scale,
respectively. These values were slightly higher at week 24
(C0.8, across the three scales and the two studies). Overall,
using recommended interpretation guidelines, measures of
reliability were homogeneously supportive of the hypothesis




The absolute value of correlations between MSQ scale
scores and HIT-6 scores was above the recommended
threshold of 0.40 for convergent validity [32] across studies
and time points, ranging between 0.59 and 0.86 (Table 4).
Table 2 Confirmatory factor analysis: completely standardized factor loadings and standard errors (SE) for the proposed three-factor mea-






1 […] have migraines interfered with how well you dealt with family, friends, and others who are close to you? 0.77 (0.02) 0.77 (0.02)
2 […] have migraines interfered with your leisure time activities, such as reading or exercising? 0.81 (0.02) 0.78 (0.02)
3 […] have you had difficulty in performing work or daily activities because of migraine symptoms? 0.86 (0.01) 0.87 (0.01)
4 […] did migraines keep you from getting as much done at work or at home? 0.82 (0.02) 0.84 (0.01)
5 […] did migraines limit your ability to concentrate on work or daily activities? 0.86 (0.01) 0.85 (0.01)
6 […] have migraines left you too tired to do work or daily activities? 0.79 (0.02) 0.79 (0.02)
7 […] have migraines limited the number of days you have felt energetic? 0.71 (0.02) 0.71 (0.02)
Role function-preventive (RP)
8 […] have you had to cancel work or daily activities because you had a migraine? 0.84 (0.02) 0.85 (0.01)
9 […] did you need help in handling routine tasks such as every day household chores, doing necessary
business, shopping, or caring for others, when you had a migraine?
0.79 (0.02) 0.79 (0.02)
10 […] did you have to stop work or daily activities to deal with migraine symptoms? 0.81 (0.02) 0.81 (0.02)
11 […] were you not able to go to social activities such as parties, dinner with friends, because you had a
migraine?
0.81 (0.02) 0.82 (0.02)
Emotional function (EF)
12 […] have you felt fed up or frustrated because of your migraines? 0.62 (0.03) 0.67 (0.03)
13 […] have you felt like you were a burden on others because of your migraines? 0.88 (0.02) 0.84 (0.02)
14 […] have you been afraid of letting others down because of your migraines? 0.79 (0.02) 0.86 (0.02)
Chi-square (DF) 265.80 (74) 235.23 (74)
CFI/TLI 0.96/0.96 0.97/0.96




Correlation (RR, RP) 0.91 0.87
Correlation (RR, EF) 0.74 0.68
Correlation (RP, EF) 0.71 0.72
CFI comparative fit index, DF degrees of freedom, RMSEA root mean square error of approximation, TLI Tucker–Lewis Index
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Known-groups validity
Mean RR, RP, and EF scale scores differed significantly in
the ANOVA model comparing patients grouped by fre-
quency of headache days per 28 days, with and without
adjusting for the presence of medication overuse (Table 5).
Similarly, a decreasing trend in mean MSQ scale scores
among patients with a greater number of headache hours
was also observed. This trend was consistent, with the
exception of the mean EF scale score among patients who
experienced greater than or equal to 420 h of headache in
study 2 (EF = 48.1), which was slightly higher than the
mean score among patients who experienced between 280
and 420 h of headache (EF = 41.6).
Responsiveness
In both studies, all three mean MSQ scale scores were
higher among patients who experienced a greater decrease
from baseline in the number of headache days (Table 6).
This effect was highly significant (p \ 0.001) in both
studies and for all three MSQ scales even after controlling
for medication overuse. Using Cohen’s standards [36] as a
guideline for interpretation, MSQ change scores indicated
large and moderate effect sizes for patients who experi-
enced C50 % improvement and improvement between 30
and 50 %, respectively. Change scores among the group
with minimal or no improvement were small or nearly null.
Table 4 Convergent/discriminant validity: correlations between
Migraine-Specific Questionnaire scale scores and scores on the
Headache Impact Test-6
Scale Study 1 Study 2
Pearson N Pearson N
Baseline RR -0.75 670 -0.78 701
RP -0.67 670 -0.66 702
EF -0.62 671 -0.59 703
Week 24 RR -0.86 585 -0.84 646
RP -0.74 584 -0.74 647
EF -0.78 583 -0.74 647
RR role restrictive, RP role preventive, EF emotional function
Table 5 Known-groups validity: Migraine-Specific Questionnaire scale scores at week 24 in relation groups defined by chronic migraine
clinical criterion measures
Study MSQ scale Cumulative hours of headache Fa Fb
\140 h 140–\280 h 280–\420 h C420 h
Mean SD N Mean SD N Mean SD N Mean SD N
1 RR 61.5 21.9 282 44.8 19.8 149 41.1 19.8 91 34.8 22.2 65 46.7c 48.7c
RP 74.8 20.6 282 61.4 21.8 149 58.1 22.9 91 52.7 25.1 64 29.7c 30.4c
EF 65.2 28.4 280 48.4 27.7 148 42.2 27.0 91 40.5 28.5 64 27.1c 28.0c
2 RR 60.9 22.7 337 46.7 21.4 169 39.9 19.6 85 35.7 20.7 56 41.2c 40.8c
RP 73.7 21.2 337 61.1 23.5 169 55.3 23.2 85 54.2 24.3 56 27.7c 27.3c
EF 67.2 27.0 337 52.7 28.1 169 41.6 25.6 85 48.1 26.4 56 28.3c 27.8c
Study MSQ scale Number of headache days per 28 days
\10 days 10–14 days C15 days
1 RR 63.0 23.1 235 49.4 18.7 122 39.9 20.2 230 69.8c 70.3c
RP 75.6 21.1 235 66.5 20.5 122 56.9 23.2 229 43.0c 43.0c
EF 66.3 29.8 233 55.0 25.4 122 42.5 27.3 228 41.5c 41.6c
2 RR 64.5 22.3 268 47.3 21.4 148 41.1 19.9 231 80.3c 76.0c
RP 76.3 21.2 268 62.2 21.9 148 57.3 23.3 231 49.0c 45.7c
EF 71.2 26.3 268 52.8 27.6 148 47.1 25.9 231 55.9c 52.5c
MSQ Migraine-Specific Questionnaire, SD standard deviation
a F statistics and p values for between-category comparisons are from analysis of variance (ANOVA). The main effect in the ANOVA was
ranked category of decrease in the clinical criterion measure (i.e., headache days or cumulative hours), where the type III sum of squares was
used
b F statistics and p values for between-category comparisons are from analysis of variance (ANOVA). The main effects in the ANOVA included
ranked category of decrease in the clinical criterion measure (i.e., headache days or cumulative hours) and medication-overuse strata, where the
type III sum of squares was used
c p value \0.001
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The RR, which was the MSQ domain most impacted at
baseline, was slightly more responsive than the RP and EF
scales, as indicated by greater SRM values.
Discussion
The findings of the current study confirmed the appropri-
ateness of the MSQ measurement model, the tool’s con-
struct validity, and its ability to detect change in clinical
indicators of headache, across two independent samples of
CM patients undergoing prophylaxis treatment. Goodness
of fit indices and strong factor loadings indicated strong
model fit for the three-factor MSQ model. The convergent
and discriminant validity of the MSQ were also confirmed
by the finding of strong correlations (-0.59 to -0.86) with
the HIT-6, a headache-specific measure. The reliability of
the MSQ scales was found to be excellent, and item-level
reliability statistics indicated good performance for 13 of
the 14 items. Known-groups validity of all three MSQ
scales was confirmed, with statistically significant differ-
ences in MSQ scale scores observed across patient groups
Table 6 Responsiveness: average change in Migraine-Specific Questionnaire scale scores in relation to changes in number of headache days
from baseline to week 24
Percentage improvement
in headache frequency
n Mean change in MSQ SD SRM F valuea p Valuea F valueb p Valueb
Role restrictive
Study 1 (%)
C50 234 23.3 24.0 1.0 63.5 \0.001 63.4 \0.001
C30 to \50 107 12.6 20.1 0.6
\30 244 3.0 14.0 0.2
Study 2 (%)
C50 269 23.1 22.4 1.0 72.9 \0.001 71.2 \0.001
C30 to \50 116 10.6 21.8 0.5
\30 262 2.7 15.0 0.2
Role preventive
Study 1 (%)
C50 234 18.5 22.2 0.8 45.4 \0.001 45.3 \0.001
C30 to \50 107 11.2 19.0 0.6
\30 243 1.7 16.4 0.1
Study 2 (%)
C50 269 18.4 22.8 0.8 54.9 \0.001 55.4 \0.001
C30 to \50 116 8.5 20.1 0.4
\30 262 0.4 16.1 0.0
Emotional function
Study 1 (%)
C50 233 24.6 27.91 0.88 50.7 \0.001 50.6 \0.001
C30 to \50 105 14.9 23.56 0.63
\30 243 2.2 20.58 0.11
Study 2 (%)
C50 269 26.8 26.34 1.02 74.6 \0.001 73.9 \0.001
C30 to \50 116 11.0 24.84 0.44
\30 261 1.8 19.97 0.09
Percentage improvement in 28-day frequency of headache days was evaluated as
ðfrequency at week 24frequency at baselineÞ
frequency at baseline
 100
MSQ Migraine-Specific Questionnaire, SD standard deviation, SRM standardized response mean
a F statistics and p values for between-category comparisons are from analysis of variance (ANOVA). The main effect in the ANOVA was
ranked category of decrease in number of headache days, where the type III sum of squares was used
b F statistics and p values for between-category comparisons are from analysis of variance (ANOVA). The main effects in the ANOVA included
ranked category of decrease in number of headache days and medication-overuse strata, where the type III sum of squares was used
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when stratified by known clinical measures such as fre-
quency of headache days and headache hours. Respon-
siveness of the MSQ scales was demonstrated by the
association of significantly larger increases in MSQ scale
scores with greater decreases from baseline in the fre-
quency of headache days. All of our results were nearly
identical across the two studies, providing robust evidence
in favor of the MSQ’s psychometric properties among CM
patients.
Based on the relatively weaker psychometric properties
of item 12 and high correlations between the three latent
factors, alternative factor structures were investigated but
none was found to provide a better fit than the current MSQ
three-factor model. Although some of our findings
regarding item 12 are corroborated by results from another
study [9], in our study, removal of item 12 did not result in
better goodness of fit indicators. The high correlations
between the three latent factors of the MSQ that were
observed in the current study have been discussed in a
previous study [7] where significant overlap between the
RR and the RP scales was found.
Some limitations should be taken into account in the
interpretation of the study’s findings.
First, the patient sample was taken from two clinical
trials; therefore, generalizability to the general population
of CM patients may be limited. Second, the sample is
representative of those migraineurs receiving onabotuli-
numtoxinA as prophylaxis and may not be generalizable to
other migraine treatments. Finally, consistency of the
measurement model across the two studies was not tested
using a formal statistical approach. Such an approach
would have entailed the use of multigroup CFA to test the
measurement invariance of the MSQ across the two stud-
ies. Nevertheless, the similarity of both the factor loadings
and the goodness of fit indicators suggest that the results of
such tests would have confirmed measurement invariance
across the two studies.
No prior studies have evaluated the psychometric
properties of the MSQ specifically among CM patients.
The evidence presented herein, and its consistency with
results from previous studies suggests that the MSQ can be
used to reliably measure the impact of headache across the
spectrum of headache frequency, including CM.
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